What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#POS0716 #EULAR2022 Systematic review and meta-analysis of 7 studies (i.e. only 1 x proof of concept RCT) showed high SRI-4 response rate (82%) in #lupus patients treated on IL2. Injection reaction (33%) and Fever (24%). Promising and definitive RCT is needed @RheumNow https://t.co/BBcgt11yNT
Robert B Chao, MD doctorRBC
3 years 6 months ago
Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis).
@RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022
Ultrasound may be used to evaluate patients with RA (POS1393) and SSc (POS1394)
👁️Look for B-lines and pleural irregularity
Will require training of MSKUS rheumatologists, but another potential application of US in clinical practice
@RheumNow @MymaAlbaydaMD @USSONAR_Rh https://t.co/qtnBviKA3w
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#POS0713 #EULAR2022 Exploratory analyses from Phase 2 RCT showed numerically more patients treated with BIIB059, a BDCA2 inhibitor achieved a clear (CLASI of 0-1) and almost clear cutaneous #lupus (CLASI 0-3). Looking forward to Phase 3 results in the next few years @RheumNow https://t.co/dDbwYCx7zT
Dr. John Cush RheumNow
3 years 6 months ago
RheumNow’s expanded coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow
3 years 6 months ago
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/OBLt7dOMa3 https://t.co/lHmEOIFIGa
Robert B Chao, MD doctorRBC
3 years 6 months ago
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest.
@RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
TheDaoIndex KDAO2011
3 years 6 months ago
“Post-exertional fatigue is real (in #LongCovid), not their fault. Validate their symptoms. Pain is secondary.”- Dr. @LCalabreseDO #EULAR2022 @rheumnow https://t.co/hDvxJfb14f
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#POS0721 #EULAR2022 Are Aspirin + LMWH enough to prevent Adverse Pregnancy Outcomes (preterm, pregnancy loss, eclampsia) in High Risk Triple Antiphospholipid abs+ve + Low C3/C4? An Italian study of 128 patients said NO. Add Hydroxychloroquine @RheumNow https://t.co/927sZoHZEj
Dr. John Cush RheumNow
3 years 6 months ago
JAKi for nonradiographic axSpA
One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. And the question of the utility of JAK inhibitors for the treatment of axSpA has been on the rise.
https://t.co/xq8ICyKKv0 https://t.co/o2iUgyU60A
Richard Conway RichardPAConway
3 years 6 months ago
Germano et al. Temporal artery abnormality on clinical exam predicts biopsy + . Arterial thickening and reduced pulse strongest predictors @RheumNow #EULAR2022 POS0820 https://t.co/Rs36ALSoJb
Richard Conway RichardPAConway
3 years 6 months ago
Merola et al. Risankizumab on MDA and DAPSA in KEEPsAKE 1 and 2. Week 24 MDA 25.0/25.6% vs 10.2/11.4%. DAPSA LDA+REM 41.2/36.8% week 24, 59.2/44.6% week 52 @RheumNow #EULAR2022 POS1029 https://t.co/Uz7kA76pMH
Poster Hall